Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
13.15
+0.85 (6.91%)
At close: May 12, 2025, 4:00 PM
13.15
0.00 (0.00%)
After-hours: May 12, 2025, 4:01 PM EDT
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Centessa Pharmaceuticals stock have an average target of 26.11, with a low estimate of 11 and a high estimate of 38. The average target predicts an increase of 98.56% from the current stock price of 13.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 4 | 4 | 5 |
Buy | 3 | 3 | 3 | 4 | 4 | 4 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 8 | 8 | 9 | 9 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Chardan Capital | Chardan Capital | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +128.14% | May 8, 2025 |
Piper Sandler | Piper Sandler | Buy Initiates $38 | Buy | Initiates | $38 | +188.97% | Mar 31, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +112.93% | Mar 26, 2025 |
Morgan Stanley | Morgan Stanley | Buy Initiates $27 | Buy | Initiates | $27 | +105.32% | Mar 7, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.54
from -2.06
EPS Next Year
-1.65
from -1.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.27 | -1.17 | -1.08 | ||
Avg | -1.54 | -1.65 | -1.77 | ||
Low | -1.72 | -1.97 | -2.28 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.